A cross-sectional analysis of the FDA FAERS database indicates that while cutaneous adverse events associated with GLP-1 receptor agonists are statistically rare, they do occur. The most frequently reported reactions included rash, pruritus, and injection site reactions. Researchers suggest that switching from daily to weekly formulations may mitigate these skin-related side effects in sensitive patients.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.